David Wohl, MD
Co-director, UNC Regional Special Pathogen Treatment Center
Co-Director, UNC Project-Liberia
Co-director, UNC Global Clinical Trials Unit
CTU Site Leader, CRS Chapel Hill
Professor of Medicine, Division of Infectious Diseases
Areas of Interest
Optimizing HIV clinical management Emerging pathogen detection, Prevention, and Treatment
About
Dr. Wohl is a physician-clinical researcher and clinician with a career dedicated to the study and treatment of emerging infectious diseases. Prior to 2014, his clinical and research activities were almost exclusively focused on the care of people with HIV infection and HIV-related patient-oriented research. He leads a large NIAID-supported HIV Clinical Research Site (CRS) at UNC-Chapel Hill and serves as Co-PI for the UNC Global Clinical Trials Research Unit (CTU), which includes sites in North Carolina, Malawi, and Vietnam. With the Ebola virus disease outbreak in West Africa in 2014, he expanded his work to other emerging infectious diseases including Ebola and Lassa fever, and with the pandemic, SARS-CoV-2. Dr. Wohl’s interest in viral hemorrhagic fevers led to his co-founding and co-directing the UNC Project-Liberia and the establishment of its two productive research sites in this West African nation.
Education
-
Undergraduate
Boston University
-
Medical School
Robert Wood Johnson Rutgers Medical School
-
Residency
Duke University
-
Fellowship
University of North Carolina at Chapel Hill